Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Biotechnology

Healthcare
$1.03 +6.12%

+$0.06 today

Market cap
$50.06M
Beta
0.29
P/E (TTM)
-1.4
EPS (TTM)
-$0.71
52W Low $0.27High $1.83

Volume 1.85M

Average 5.09M

HOWL Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Werewolf Therapeutics, Inc.NASDAQ: HOWL

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin at 40.7%

Operating margin was 40.7% in Q2 FY2026. On a trailing-twelve-month basis it was -121.8%.

Context

  • Operating margin widened in 1 of the last 2 fiscal years.
  • FY2024 was the lowest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
40.7%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMJun 2026
-121.8%— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2024
-3904.2%
Year-over-year change
-3701.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How HOWL compares with its peers on the latest reported figures

  • HOWL's LTM Jun 2026 operating margin of -121.8% is the 2nd highest of the 5 companies compared; the peer median is -9466.2%.
HOWL Competitors Peer median
Operating Margin for HOWL and competitors
Company Period LTM level YoY 3-year change
CUECue Biopharma, Inc.LTM Mar 2026-59.8% +454.9 pp+4178.5 pp
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026-121.8% ——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-749.7% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18182.8% +26748.2 pp—
INMBINmune Bio, Inc.FY2025-61738.0% +242797.7 pp-54799.2 pp
SPRBSpruce Biosciences, Inc.FY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
Peer median (excluding HOWL) -9466.2%+26748.2 pp-25310.3 pp

Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue016.4M19.94M1.89M0
Cost of Revenue02.51M1.76M1.81M1.63M
Gross Profit013.89M18.18M71K(1.63M)
Gross Margin—84.7%91.2%3.8%—
Research & Development35.27M53.76M41.78M56.43M44.83M
Selling, General & Admin14.82M21.5M18.67M19.05M15.85M
Operating Expenses50.09M69.95M58.68M73.67M59.04M
Depreciation & Amortization216K1.1M1.76M1.81M1.63M
EBITDA(49.77M)(52.71M)(32.47M)(64.05M)(53.91M)
EBITDA Margin—-321.4%-162.8%-3397.6%—
Operating Income(50.09M)(56.06M)(40.5M)(73.59M)(60.68M)
Operating Margin—-341.8%-203.1%-3904.2%—
Interest Income104K1.91M7.42M6.67M3.11M
Interest Expense003.14M4.66M5.27M
Other Income / Expenses104K2.25M3.14M3.08M(145K)
Income Before Tax(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Pre-Tax Margin—-328.1%-187.4%-3740.8%—
Income Tax Expense00000
Net Income(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Net Margin—-328.1%-187.4%-3740.8%—
EPS (Basic)(10.94)(1.86)(1.05)(1.63)(1.32)
EPS (Diluted)(10.94)(1.86)(1.05)(1.63)(1.33)
Weighted Avg Shares18.46M28.86M35.65M43.33M46.02M
Weighted Avg Shares (Diluted)18.46M28.86M35.65M43.86M46.81M

Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.